H.C. Wainwright raised the firm's price target on Relay Therapeutics to $28 from $25 and keeps a Buy rating on the shares after the company presented initial results from the ongoing Phase 2 ReInspire trial evaluating zovegalisib in adults and adolescents with PIK3CA-driven vascular anomalies. The firm believes the results may position zovegalisib as the "go-to option for PIK3CA-driven vascular anomalies should they be recapitulated in dose expansion."
